Abstract

With the development of understanding of the pathogenesis of rheumatoid arthritis, it has led to the development of new treatment targets and new treatment guidelines. In the past 10 years, the treatment effect of RA patients has improved significantly. Due to the special clinical symptoms of RA, it is very important to have a clear assessment of the overall activity of the patient’s disease and timely adjustment of treatment through joint monitoring of symptoms and laboratory indicators. Clinicians have always relied on clinical manifestations and imaging progress as the key basis for diagnosis. In addition, some markers that reflect disease activity are used to aid the diagnosis of RA, but in other autoimmune diseases, these markers are usually increased. The emergence of specific autoantibodies makes it easier for clinicians to distinguish RA from other autoimmune diseases and osteoarthritis. This study collected a large number of medical records through retrospective analysis, analyzed the epidemiological data, clinical characteristics, and laboratory indicators of RA patients, and analyzed the characteristics and laboratory indicators of patients in the stable disease group and active disease group. In order to further understand the clinical features, disease activity and related factors of RA in our country, and some new biomarkers for early rheumatoid arthritis, for example, the study found that the specificity of RF for the diagnosis of RA was 71.1%, the sensitivity was 73.3%, the combined detection of anti-CCP antibody + RF increased the specificity to 97.8%, and anti-CCP the combined diagnosis of antibody+RF + GPI antigen increases the specificity of diagnosis to 100%, which significantly reduces the sensitivity compared with all tests. These autoimmune antibodies can more effectively prevent the progression of the disease in the early diagnosis and treatment of rheumatoid arthritis, achieve long-term remission, and obtain very effective therapeutic effects.

Highlights

  • The application of magnetic resonance imaging is to see the pathological changes of early rheumatoid arthritis, and bone marrow edema is a special imaging of rheumatoid arthritis, which is very useful for the diagnosis of early rheumatoid arthritis

  • (1) This paper studies the detection of serum anti-PDI4 antibody levels and found that the level and positive rate of anti-PLD4 antibodies in the PA group are higher than those in the non-Rheumatoid arthritis (RA) group and healthy controls, indicating that the antibody RAD4 is an autoantibody for rheumatoid arthritis and can be used for serology The new effective markers detected are used for the diagnosis and differential diagnosis of RA

  • The results showed that compared with the other two groups, the concentrations of anti-MCV antibody, GPI antigen, anti-cyclic citrullinated peptide antibodies (CCP) antibody, and Rheumatoid factor (RF) in the RA group were significantly higher (p < 0:05)

Read more

Summary

Introduction

People have adopted a variety of methods to discover some new biomarkers in the early stages of rheumatoid arthritis, which provides a basis for the early diagnosis and treatment of RA, thereby improving joint function, improving work ability, and improving life. The combination of RF, anti-CCP antibody, AKA, and anti-PADI4 antibody can provide a lot of clinical diagnostic information (3) In this article, by detecting the level of DKK-1 in the serum of patients with rheumatoid arthritis and healthy individuals, and analyzing its correlation with the results of clinical trials, bone density determination, and other related tests, the expression level of DKK-1 in the serum of RA patient preliminary exploration and related clinical significance provides clinical evidence for the clinical application of DKK-1

Early Diagnosis of Autoimmune Antibodies
Comprehensive Medical System for Early Diagnosis of Autoimmune Antibodies
Test Design
Effect of the Early Diagnosis System of Autoimmune Antibodies
Comparison of Sensitivity and Specificity of Serum
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call